Tesamorelin’s VAT loss: promising marker, uncertain performance

Posted by mom984 in GH & Growth Peptides - 2 points, 0 comments.

https://www.ncbi.nlm.nih.gov/books/NBK539136

The NCBI Bookshelf review breaks down the FDA’s stance on tesamorelin – it clearly cuts visceral abdominal fat in HIV‑related lipodystrophy, but the agency admits the real‑world health benefit of that reduction is still up in the air. The paper walks through three trials, all of which excluded anyone on other GH‑secretagogues, and points out that while the biomarker changes are solid, we don’t yet know if they translate into lower cardiovascular risk or better metabolic health.

For me the article feels spot‑on about the hype gap. I’ve tried a low‑dose ipamorelin/CJC‑1295 stack for a few months and noticed a subtle improvement in sleep quality and recovery, but I’ve never seen a dramatic change in waist size. Tesamorelin’s data look cleaner because it’s a pure GHRH analogue, yet the lack of hard outcomes makes me hesitant to recommend it beyond the approved HIV population. The cost and need for daily injections also scream “niche” to me. I’d love to see a longer‑term study that measures hard endpoints like insulin sensitivity or heart health in otherwise healthy folks.

Has anyone here tracked blood work or body‑composition changes on tesamorelin outside of the HIV context? What markers would you monitor to decide if the visceral fat loss is actually worth the effort?

Community discussion - research and educational context only. Not medical advice.